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ABSTRACT
Background. The harm caused by the long interdialytic interval in three-times-per-week haemodialysis regimens (3WHD)
may relate to fluid accumulation and associated high ultrafiltration rate (UFR). Four-times-per-week haemodialysis
(4WHD) may offer a solution, but its impact on mortality, hospitalization and vascular access complications is unknown.
Methods. From the AROii cohort of incident in-centre haemodialysis patients, 3WHD patients with a UFR >10mL/kg/h were
identified. The hazard for the outcomes of mortality, hospitalization and vascular access complications in those who
switched to 4WHD compared with staying on 3WHDwas estimated using a marginal structural Cox proportional
hazards model. Adjustment included baseline patient and treatment characteristics with inverse probability weighting
used to adjust for time-varying UFR and cardiovascular comorbidities.
Results. From 10 637 European 3WHD patients, 3842 (36%) exceeded a UFR >10mL/kg/h. Of these, 288 (7.5%) started 4WHD
and at baseline were more comorbid. Event rates while receiving 4WHD compared with 3WHDwere 12.6 compared with
10.8 per 100 patient years for mortality, 0.96 compared with 0.65 per year for hospitalization and 14.7 compared with 8.0 per
100 patient years for vascular access complications. Compared with 3WHD, the unadjusted hazard ratio (HR) for mortality
on 4WHDwas 1.05 [95% confidence interval (CI) 0.78–1.42]. Following adjustment for baseline demographics, time-varying
treatment probability and censoring risks, this HR was 0.73 (95% CI 0.50–1.05; P¼0.095). Despite these adjustments on
4WHD, the HR for hospitalization remained elevated and vascular access complications were similar to 3WHD.
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Conclusions. This observational study was not able to demonstrate a mortality benefit in patients switched to 4WHD. To
demonstrate the true benefits of 4WHD requires a large, well-designed clinical trial. Our data may help in the design of
such a study.
Keywords: four-times-per-week haemodialysis, hospitalization, survival analysis, ultrafiltration, vascular access
INTRODUCTION
For the majority of in-centre haemodialysis (HD) patients, a
three-times-per-week HD (3WHD) schedule is unphysiological
with interdialytic intervals of between 48 and 72h. Harm associ-
ated with the accumulation of uraemic toxics, potassium and
fluid may manifest in increases in arrhythmias [1], cardiac fail-
ure [2], hospitalization, mortality and symptom burden [3–5].
More intensive HD theoretically mitigates some of these harms.
Observational data suggest that 3WHD with a longer session
length is associated with improved overall survival, but
increases in mortality after the long interdialytic interval persist
[6]. Obtaining outcome data on benefits of more frequent dialy-
sis through clinical trials has proven challenging [7]. Six-times-
per-week HD may be clinically beneficial and cost effective but
is only practical in a subgroup of patients [8–11].
Recent analyses suggest that compared with the short inter-
dialytic interval, the longer 2-day interdialytic interval is associ-
ated with increases in hospitalization and mortality of 80–100%
[12]. Specifically targeting this period with an additional dialysis
session may be attractive both to providers and to patients:
one-fifth of patients who report being bothered by their fluid re-
striction state that they would accept an additional HD session
if offered it [13]. Four-times-per-week HD (4WHD) is the third
most commonly prescribed HD frequency after three- and two-
times-per-week schedules; however, previous evaluations have
combined 4WHD with other augmented regimes such as ex-
tended-hours dialysis, making the impact of the discrete re-
moval of the long interdialytic interval challenging [14].
We present a target trial observational data analysis where a
large dataset was used to emulate the desired clinical trial with
inclusion and exclusion criteria, follow-up time, adherence and
endpoints reflecting benefits and harms [15, 16]. Identifying
high-risk individuals using the ultrafiltration rate (UFR) repre-
senting the clinical driver to initiate 4WHD [17], it employs
marginal structural modelling [18] to address the relationship
between UF and the risk of initiating of 4WHD and mortality,
which may lead to biased estimates of the benefits of treatment.
This study design recognizes the clinical indications to offer a
3WHD patient a regular additional session, appropriately fac-
toring in the variables that are associated with the time-varying
risk of events the clinician and patient are trying to avoid.
MATERIALS AND METHODS
Cohort and data
The Analyzing Data, Recognizing Excellence and Optimizing
Outcomes (ARO) cohort was a prospective observational cohort
study of electronic medical records capturing anonymized lon-
gitudinal individual-level data for incident HD patients enrolled
at 1 of the 312 Fresenius Medical Care (FMC) facilities across 15
European countries between 2007 and 2009 and followed up un-
til the end of 2014. All local ethical and regulatory obligations
concerning patient data for each of the 15 participating coun-
tries were met. These approvals encompass subsequent
analyses including those described here. Informed consent was
obtained from all patients by FMC (Europe).
Data on demographics, comorbidities, laboratory results,
hospitalizations, mortality and individual HD sessions were
captured [19]. The presence of 11 comorbid conditions was iden-
tified using International Classification of Diseases, Tenth revi-
sion (ICD-10) codes from administrative data using existing
schema (ischaemic heart disease, congestive heart failure, cere-
brovascular accident, peripheral vascular disease, other cardiac
disease, chronic obstructive pulmonary disease, gastrointesti-
nal bleeding, liver disease, dysrhythmia, cancer and diabetes
[20]). Hospitalization was defined as an admission to hospital
lasting at least 1 day. Within these hospitalizations, ICD-10
codes for vascular access complications were identified (see Sup
plementary data, Table S1, for associated ICD-10 codes).
Eligibility, exposure, adherence and follow-up
The inclusion criteria of an UFR >10 mL/kg/h was based on the
progressive mortality increase associated with this range of UF
[17]. Patients were classed as eligible for 4WHD and included
in the analysis from the point they exceeded this UFR across
three HD sessions while prescribed 3WHD. The UFR was calcu-
lated for each session from the recorded difference in pre- and
post-dialysis weights divided by treatment time in minutes.
There were no clinical exclusion criteria. Exposure to 4WHD
was classed as receiving four HD sessions in week 1, four ses-
sions per week 4 weeks later and a further four sessions per
week 2 weeks after that. This was in order to address any incor-
rect identification of 4WHD associated with rescheduling HD
for elective admissions or ad hoc HD to address specific issues.
Adherence was assessed while receiving 3WHD and 4WHD
using the mean number of delivered sessions per week.
Attendance for HD was defined as the presence of a recording
for blood pressure, pre-dialysis weight and HD treatment time.
Follow-up was up to 3 years from the date of first eligibility or
until censoring for transplantation, moving to a non-FMC facil-
ity, changing dialysis modality, withdrawal of consent or death.
Statistical methods
During the course of the analysis, an individual’s dialysis fre-
quency (moving from 3WHD to 4WHD) and the clinical
parameters that are associated with this change in frequency
and also the outcomes (e.g. increasing UFR) vary. Marginal
structural Cox proportional hazards models were used to esti-
mate the time-varying association between dialysis frequency
(4WHD versus 3WHD) and the endpoints of mortality, hospi-
talization and hospitalization for vascular access complications.
Marginal structural models are designed to account for con-
founding introduced by time-varying clinical parameters and
their response to treatment over time by weighting an individ-
ual patient’s observations to create a pseudo-population where
time-varying covariates are more evenly distributed between
treatment arms. They still assume there are no unmeasured
confounders. First, logistic regression was used to obtain



















































































probabilities of treatment (switching from 3WHD to 4WHD)
and censoring (transplantation or being lost to follow-up) for
each month from inclusion in the study by meeting the eligibil-
ity until the end of follow-up [18, 21]. Baseline covariates
(comorbidities at eligibility, achieved dialysis session duration,
dialysis catheter use, equilibrated Kt/V, time on dialysis, age, se-
rum phosphate level and post-dialysis weight) and time-
varying covariates (UFR, systolic blood pressure and the comor-
bidities of congestive heart failure and ischaemic heart disease,
which varied within individuals during their follow-up) were in-
cluded. Continuous variables were split by quantiles into five
equal groups. Probabilities from these logistic regression models
were converted into weights by dividing the probabilities esti-
mated from the baseline covariates (numerator) by the probabil-
ities estimated using the baseline and time-varying covariates
(denominator). Treatment and censoring weights were calcu-
lated separately and multiplied together, resulting in stabilized
weights with a mean of 1.006 [standard deviation (SD) 0.174].
The final marginal structural models were adjusted for baseline
covariates because they appeared in both the numerator and
the denominator of the stabilized weights [18, 21]. The time-
varying data include a variable reflecting if the patient is receiv-
ing 3WHD or 4WHD and weights were set to 1 following the
initiation of 4WHD [18]. The hazard for the endpoints associ-
ated with the time-varying exposure to 4WHD is reported fol-
lowing sequential adjustment: (1) adjusted for baseline
covariates, which leaves residual confounding, because clinical
parameters and their response to treatment vary over time; (2)
adjusted for time-varying covariates using inverse probability
weighting for treatment; and (3) employing weighting to ad-
dress the time-varying risk of being censored by transplantation
or lost to follow-up, which may be associated with the out-
comes of interest. Proportional hazards assumptions were
assessed graphically using Schoenfeld residuals. When time-
varying laboratory and HD data were missing we used the last-
observation-carried forward approach (2.97% and 1.42% of pa-
tient follow-up time beyond 35 and 3days, respectively); as in
clinical practice, decisions to initiate 4WHD may be made
from historical observations. Patients with missing data at the
time of death were excluded entirely, which only affected 14
patients who never received 4WHD.
In the main analysis, patients who were exposed to 4WHD
were treated as receiving this until the end of follow-up, as ad-
verse consequences of 4WHD (which may manifest once a pa-
tient returns to 3WHD) would then be captured. A sensitivity
analysis was performed to explore any modification of the ef-
fect of 4WHD accounting for patients who receive the treat-
ment but return to 3WHD, whereby patients who moved from
4WHD back to 3WHD were treated as on 3WHD from
3months after the observed treatment switch. Reverting to
3WHD was defined as 3 consecutive non-hospitalized weeks
receiving 3 sessions per week. This lagged per-protocol analy-
sis assigned any events occurring within the 3 months of
switching from 4WD back to 3WHD to the 4WHD treat-
ment. Statistical analyses were conducted in R version 3.4.4 (R
Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patient characteristics
A total of 10 637 incident HD patients were screened for inclu-
sion in the study, with 4009 (37.7%) patients meeting the inclu-
sion criteria of an average UFR across three HD sessions
>10mL/kg/h following a median of 6.1months of HD. Figure 1A
shows the proportion of patients on 3WHD with a UFR
<10mL/kg/h, 3WHD with a UFR >10mL/kg/h (eligible for
4WHD), transplanted, lost to follow-up or died. The prevalence
of patients eligible for 4WHD stabilizes at 20–25% following
12months of HD.
Having exceeded a UFR of 10mL/kg/h and classed as eligible
for 4WHD, 7.5% of patients subsequently went on to receive
4WHD and were suitable for analysis. The prevalence of
patients receiving 4WHD stabilized at 4% after ~12months, as
new patients commenced 4WHD and patients on 4WHD left
the study (Figure 1B). Patient flow through the screening pro-
cess, inclusion criteria, subsequent treatment and inclusion in
the analysis are shown in Figure 2. The demographics of
patients who remained on 3WHD or subsequently went onto
4WHD having met the inclusion criteria are illustrated in
Table 1, showing baseline differences in age (62.5 versus
60.8 years), diabetes (34.7% versus 48.3%), weight (64.5 and
Died
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FIGURE 1: (A) The prevalence of patients meeting the inclusion criteria (10mL/kg/h UFR) for the four-times-per-week target trial. (B) The proportion of patients meeting
the inclusion criteria who go on to receive 4WHD, and other competing events.



















































































68.2 kg) and heart failure (16.4% versus 21.5%). The numbers of
patients from each country are available in the Supplementary
Materials.
Both at baseline and during follow-up, there were differen-
ces in the prevalence of cardiovascular comorbidity and the pro-
portion of patients who were transplanted or lost to follow-up
between the time patients received 3WHD (Figure 3A) and
4WHD (Figure 3B). These time-varying associations support
the use of inverse probability weighting methods for treatment
and censoring. The demographics of patients according to their
reasons for exiting the study are listed in Supplementary data,
Table S2.
Treatment initiation and adherence
In those who received it, 4WHD was initiated a median of
12.5months from the time patients first became eligible. From 6
weeks following the initiation of 4WHD treatment, the median
time from the initiation of 4WHD to the end of follow-up or 3
consecutive weeks receiving less than four sessions per week
was 6.1months. For the duration of follow-up, the average num-
ber of sessions delivered per week, excluding hospitalized time,
was 3.46 sessions per week in the 4WHD arm and 2.96 ses-
sions per week in the 3WHD arm. The mean session duration
was 229min while receiving 4WHD and 235min while receiv-
ing 3WHD.
Associations with mortality, hospitalization and
vascular access complications
The crude mortality rate during follow-up was 10.8 per 100 pa-
tient years [95% confidence interval (CI) 10.1–11.6] while receiv-
ing 3WHD and 12.6 per 100 patient years (95% CI 9.3–16.7)
following the start of 4WHD. The univariate hazard for sur-
vival while receiving 4WHD compared with 3WHD was 1.05
(95% CI 0.78–1.42; P¼ 0.735). The hazard ratio (HR) was 0.90 (95%
CI 0.65–1.24; P¼ 0.518) after adjustment for baseline covariates
and the final multivariable adjusted HR was 0.81 (95% CI 0.58–
1.14; P¼ 0.229) after adjusting for time-varying covariates using
inverse probability weighting for treatment. After weighting
for censoring risk, this multivariable HR was 0.73 (95% CI 0.50–
1.06; P¼ 0.096). These sequential adjustments are shown in
Figure 4A.
The crude hospitalization rate during follow-up was 0.65
(95% CI 0.64–0.67) per patient year while receiving 3WHD and
was 0.96 (95% CI 0.86–1.06) per patient year while receiving
4WHD [univariate HR 1.51 (95% CI 1.28–1.77), P¼ 0.008].
Following adjustment for baseline and time-varying factors
influencing treatment and censoring, 4WHD had a multivari-
able HR of 1.28 (95% CI 1.06–1.53; P¼ 0.008).
The crude vascular access complication rate was 8.0 (95% CI
7.3–8.7) per 100 patient years while receiving 3WHD and was
14.7 (95% CI 11.1–19.1) per 100 patient years while receiving
4WHD [univariate HR 1.91 (95% CI 1.50–2.61), P< 0.001].
Sequential adjustments resulted in a final multivariable HR as-
sociated with 4WHD of 1.15 (95% CI 0.78–1.72; P¼ 0.478) and
are shown in Figure 4B and C.
The sensitivity analysis exploring the medium-term impact
of switching from 4WHD back to 3WHD did not significantly
alter the effect sizes for the HR associated with the 4WHD
treatment strategy (Figure 5).
DISCUSSION
This study is the first to explore the association between
4WHD and endpoints important to clinicians and patients [15,
18, 22]. Thirty-six percent of 3WHD patients experienced the
high UFRs associated with myocardial stunning and increased
mortality [17, 23] and are the subjects of performance indicators
for dialysis clinics [24]. Despite this, only 7.5% went on to re-
ceive 4WHD for at least 6weeks. Patient characteristics pre-
dicting mortality and transplantation were less favourable in
those who received 4WHD, and accounting for this, 4WHD
was not associated with an improvement in survival. Vascular
access complications were comparable following adjustment
and hospitalization remained elevated when compared with
patients with high UF on 3WHD.
The favourable survival HR of 0.73 (95% CI 0.50–1.05;
P¼ 0.095) observed with 4WHD should be cautiously inter-
preted alongside HRs of 0.54, 3.88 and 0.91 for the 12-month
interventions in the Frequent Hemodialysis Network (FHN)
Frequent, Nocturnal and ACTIVE (A Clinical Trial of IntensiVE
Dialysis) studies, respectively [8, 25, 26]. Statistical bodies and
prominent journals recommend that estimates of effects and
their margins of error should be interpreted together to inform
clinicians and regulatory agencies regarding an intervention,
with less reliance on the absolute P-value [27–29]. One of the pri-
mary reasons to initiate 4WHD is to modify the increase in
mortality after the 2-day break in 3WHD [3, 4]. If this short-
term increase is reduced to that of the rest of the week com-
pared with a dialysis week with this short-term increase pre-
sent, the HR is only 0.88 (Appendix 1 of Supplementary
Materials).
The potential mechanisms through which the 4WHD
schedule improves outcomes could be through reductions in
the UFR and hyperkalaemia, lower time-averaged volume over-
load and myocardial stunning and reduced arrhythmias in the
build up to and during the first HD session of the dialysis week
[1, 17, 23, 30, 31]. A previous 12-month randomized trial of alter-
nate-day dialysis with no long interdialytic interval showed
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FIGURE 2: Incident patients screened throughout their follow-up and their flow
through the analysis.



















































































pressure compared with 3WHD [32]. The extended-hours in-
tervention (predominantly extended sessions 3WHD) in the
ACTIVE trial showed reductions in left ventricular mass in those
individuals who had a reduction in UFR, although UFR and pa-
tient survival were not improved in those randomized to ex-
tended hours [26, 33]. However, augmented HD may be
associated with potential harms: the FHN short daily trial was
associated with improved survival in contrast to the nocturnal
study’s inferior survival [8, 25], and both tended towards a
higher incidence of vascular access complications in the inter-
vention arms [9, 34]. In our analysis, the increase in vascular ac-
cess events in patients receiving 4WHD was largely mitigated
following adjustment, suggesting the patient characteristics
that predict the vascular access complications and the clinical
need for 4WHD are similar.
The strengths of this analysis include the incident nature of
the cohort and the use of highly granular data to define inclu-
sion criteria, exposure to the intervention, adherence and out-
comes, further capitalized on by the target trial methodology
and marginal structural modelling approach. Although less
prone to bias, the limitation of these methods is that they deal
with observed confounders and residual unobserved differences
between patients, which could introduce bias. Other
weaknesses include the absence of information on residual kid-
ney function and quality of life. Our definition of 4WHDmeans
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FIGURE 4: HR of 4WHD compared with 3WHD for the endpoints of mortality, hospitalization and vascular access complication. Adjustment for baseline covariates
(comorbidities at eligibility, dialysis session duration, dialysis access type, equilibrated Kt/V, time on dialysis, age, serum phosphate level and post-dialysis weight) and
time-varying covariates (UFR, systolic blood pressure and the comorbidities of congestive heart failure and ischaemic heart disease) are sequentially reported.
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FIGURE 5: Sensitivity analysis comparing the HR for 4WHD compared with
thr3WHD when patients who return to 3WHD are treated as receiving this
schedule from 3 months after the switch.



















































































that those who did not adhere within the first 6weeks were not
included. The median duration of 4WHD was 6months before
the end of follow-up and we are unable to say with confidence
what outcomes might be associated with longer treatment or
sustained adherence. Our per-protocol analysis excluding
follow-up time after 4WHD patients returned to 3WHD
yielded similar effect sizes and statistical significance as the
main analysis and suggests a legacy effect that was observed in
the FHN daily trial but not the ACTIVE trial [8, 26].
Building on the existing observational data on UFR, this
study could be used to advise patients on potential interven-
tions once a UF threshold of 10mL/kg/h is reached. However, in
our study it took up to a year from patients meeting this thresh-
old to the initiation of 4WHD, suggesting other factors may in-
form the decision-making process, such as struggling with fluid
restriction and subsequent hospitalization for fluid overload [6].
The mean duration of 6 months for 4WHD suggests that some
clinicians are using this treatment in response to subacute
issues that then resolve. The more widespread sustained adop-
tion of 4WHD would have staffing and capacity implications,
which may be offset by the increasing adoption of incremental
HD start, with schedules of less than three sessions per week
[35]. Other capacity-generating initiatives such as shared- and
self-care HD programmes and the more widespread use of
home HD may offer solutions [36]. Taken together with the find-
ing of other augmented HD clinical trials [7, 10, 37], our results
could help in the design of a prospective trial evaluation of
4WHD: to demonstrate this HR with an 80% power, a ¼ 0.05
and a 10% transplantation rate at 3 years would require 833
patients per arm, improving to 479 per arm by relaxing a (0.1)
and significance to one-sided [38]. Sample sizes could be further
reduced by adjustment for baseline variables such as cardiac
failure [39], and stratification by suitability for transplantation
should be considered.
With the mounting evidence of the range of harms associ-
ated with a long interdialytic interval, this study contributes to
the supporting evidence for potential solutions; however, ap-
propriately designed studies are required to ensure they are
both clinically and cost effective, sustainable and acceptable to
the patient.
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Table 1. Demographics of patients at inclusion (10mL/kg/hr UFR) and at exposure to 43WHD
Characteristics 3WHD at eligibility 4WHD at eligibility 4WHD at initiation
Patients, n 3554 288 288
Age (years), mean (SD) 62.5 (14.9) 60.8 (15.3) 62.40 (15.37)
Male, n (%) 2148 (60.4) 159 (55.2) 159 (55.2)
Days on dialysis, mean (SD) 355.2 (417.0) 221.7 (221.6) 803.9 (596.6)
Ischaemic heart disease, n (%) 563 (15.8) 40 (13.9) 52 (18.1)
Cancer, n (%) 260 (7.3) 22 (7.6) 26 (9.0)
Heart failure, n (%) 582 (16.4) 62 (21.5) 71 (24.7)
Chronic obstructive pulmonary disease, n (%) 234 (6.6) 20 (6.9) 23 (8.0)
Cerebrovascular disease, n(%) 350 (9.8) 34 (11.8) 40 (13.9)
Depression, n (%) 69 (1.9) 8 (2.8) 8 (2.8)
Diabetes, n (%) 1232 (34.7) 139 (48.3) 142 (49.3)
Arrhythmia, n (%) 335 (9.4) 37 (12.8) 50 (17.4)
Gastrointestinal disease, n (%) 76 (2.1) 5 (1.7) 6 (2.1)
Liver disease, n (%) 132 (3.7) 13 (4.5) 15 (5.2)
Other cardiac disease, n (%) 39 (1.1) 5 (1.7) 7 (2.4)
Peripheral vascular disease, n (%) 542 (15.3) 43 (14.9) 68 (23.6)
Ultrafiltration volume (L), mean (SD) 2.72 (1.00) 2.92 (0.80) 2.48 (1.01)
UFR (mL/kg/h), mean (SD) 11.00 (3.59) 11.37 (2.83) 9.61 (3.72)
Equilibrated Kt/V, mean (SD) 1.42 (0.30) 1.36 (0.30) 1.44 (0.29)
Phosphate, mean (SD) 1.55 (0.47) 1.61 (0.48) 1.54 (0.52)
HD session duration (min), mean (SD) 231.91 (16.98) 228.95 (17.46) 230.59 (20.50)
Loop diuretic use, n(%) 329 (9.3) 34 (11.8) 37 (12.8)
Weight (kg), mean (SD) 64.48 (12.83) 68.22 (14.13) 68.09 (14.24)
Systolic blood pressure (mmHg), mean (SD) 137.16 (22.90) 141.10 (23.96) 138.81 (25.58)
Diastolic blood pressure (mmHg), mean (SD) 71.17 (13.72) 71.64 (13.96) 69.42 (14.71)
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